Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | FADS1 | O60427 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PNLIP | P16233 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744848 | 0.91 | PTGS1 (0.75) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL4954215 | 0.88 | PTGS1 (0.67) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL7058035 | 0.87 | RAB9A (0.79) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL15361168 | 0.86 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL1961258 | 0.86 | FADS1 (0.69) | NPC1RAB9ASMN1; SMN2HSD17B10PTGS1 | |
| SCHEMBL2127535 | 0.86 | PTGS1 (0.69) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL30830441 | 0.86 | PTGS1 (0.69) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL1140055 | 0.85 | PTGS1 (0.68) | NPC1RAB9AHSD17B10TP53LMNA | |
| SCHEMBL4957349 | 0.84 | LMNA (0.69) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL31424193 | 0.83 | MEN1 (0.72) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | claimed |
| CN-118184588-A | N-aryl/alkyl quinazolinone compound and synthesis method thereof | 陕西科技大学 | 2024-06-14 | — | — | CN | claimed |
| CN-104744379-B | A kind of quianzolinones and its synthetic method | 三峡大学 | 2017-10-27 | — | — | CN | claimed |
| CN-104829543-B | A kind of 2 (4 oxoalkyl group) quianzolinones and its synthetic method | 三峡大学 | 2017-08-25 | — | — | CN | claimed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-118652285-A | Preparation method of trisubstituted ferrocene derivative | 华侨大学 | 2024-09-17 | — | — | CN | disclosed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885SMN1; SMN2 3410/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | NPC1 451/4885RAB9A 1687/4885SMN1; SMN2 2491/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885SMN1; SMN2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.